

CITATION REPORT

List of articles citing

A phase III randomized trial of gantenerumab in prodromal Alzheimerts disease

DOI: 10.1186/s13195-017-0318-y
Alzheimerts Research and Therapy, 2017, 9, 95.

Source: <https://exaly.com/paper-pdf/68491244/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|----|-----------|
| 326 | The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging. 2018 , 63, 35-52 | | 58 |
| 325 | Present and Future Therapies for Alzheimer's Disease. 2018 , | | |
| 324 | Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. 2018 , 8, S59-S64 | | 38 |
| 323 | Alzheimer's disease: The right drug, the right time. 2018 , 362, 1250-1251 | | 80 |
| 322 | Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 96 | 9 | 61 |
| 321 | Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 99 | 9 | 7 |
| 320 | Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease. 2018 , 18, 1189-1192 | | 9 |
| 319 | Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 90 | 9 | 11 |
| 318 | Early AβHbc virus-like particles immunization had better effects on preventing the deficit of learning and memory abilities and reducing cerebral Aβload in PDAPP mice. 2018 , 36, 5258-5264 | | 1 |
| 317 | The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease. 2018 , 10, 118 | | 140 |
| 316 | Recent advancements toward therapeutic vaccines against Alzheimer's disease. 2018 , 17, 707-721 | | 29 |
| 315 | Alzheimer's disease: Only prevention makes sense. 2018 , 48, e13005 | | 25 |
| 314 | Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. 2018 , 64, S535-S546 | | 17 |
| 313 | Therapeutic strategies for targeting neurodegenerative protein misfolding disorders. 2018 , 44, 66-74 | | 16 |
| 312 | Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: A systematic review with meta-analysis. 2019 , 19, 475-480 | | 5 |
| 311 | Targeting the transferrin receptor for brain drug delivery. 2019 , 181, 101665 | | 96 |
| 310 | Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. 2019 , 3, 179-218 | | 9 |

| | | |
|-----|---|------|
| 309 | Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force. 2019 , 6, 157-163 | 39 |
| 308 | Anti-A β Antibodies and Cerebral Amyloid Angiopathy Complications. 2019 , 10, 1534 | 13 |
| 307 | Linking late life depression and Alzheimer’s disease: mechanisms and resilience. 2019 , 6, 103-112 | 6 |
| 306 | Pre-analytical stability of novel cerebrospinal fluid biomarkers. 2019 , 497, 204-211 | 8 |
| 305 | Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities. 2019 , 8, 777-791 | 19 |
| 304 | Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease. 2019 , 17, 1309-1317 | 36 |
| 303 | History and progress of hypotheses and clinical trials for Alzheimer’s disease. 2019 , 4, 29 | 182 |
| 302 | Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions. 2019 , 71, 715-732 | 58 |
| 301 | AD molecular: PET amyloid imaging across the Alzheimer’s disease spectrum: From disease mechanisms to prevention. 2019 , 165, 63-106 | 4 |
| 300 | The "rights" of precision drug development for Alzheimer’s disease. <i>Alzheimer’s Research and Therapy</i> , 2019 , 11, 76 | 9 93 |
| 299 | Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. 2019 , 179, 312-339 | 721 |
| 298 | Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease. 2019 , 72, S145-S176 | 19 |
| 297 | Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?. 2019 , 20, | 62 |
| 296 | A short perspective on the long road to effective treatments for Alzheimer’s disease. 2019 , 176, 3636-3648 | 9 |
| 295 | Current and Prospective Treatments for Alzheimer’s Disease (and Other Neurodegenerative Diseases). 2019 , 391-442 | 1 |
| 294 | Natural Products in Alzheimer’s Disease Therapy: Would Old Therapeutic Approaches Fix the Broken Promise of Modern Medicines?. 2019 , 24, | 41 |
| 293 | Intravenous Immunoglobulin for Patients With Alzheimer’s Disease: A Systematic Review and Meta-Analysis. 2019 , 34, 281-289 | 5 |
| 292 | Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. 2019 , 101, 1003-1015 | 18 |

| | | | |
|-----|--|---|-----|
| 291 | Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. 2019 , 92, 329-337 | | 144 |
| 290 | The Role of Biomarkers in Alzheimer's Disease Drug Development. 2019 , 1118, 29-61 | | 40 |
| 289 | Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. 2019 , 33, 104-112 | | 8 |
| 288 | Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A β (1-42), pTau and tTau CSF immunoassays. 2019 , 9, 19024 | | 50 |
| 287 | Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A β <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 97 | 9 | 4 |
| 286 | Gantenerumab reduces amyloid- β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 101 | 9 | 63 |
| 285 | Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. 2019 , 33, 99-106 | | 24 |
| 284 | Astrocyte Biomarkers in Alzheimer's Disease. 2019 , 25, 77-95 | | 108 |
| 283 | A critical appraisal of amyloid- β targeting therapies for Alzheimer's disease. 2019 , 15, 73-88 | | 387 |
| 282 | Are antibodies directed against amyloid- β oligomers the last call for the A β hypothesis of Alzheimer's disease?. 2019 , 11, 3-6 | | 39 |
| 281 | Cerebral Amyloid Angiopathy and Neuritic Plaque Pathology Correlate with Cognitive Decline in Elderly Non-Demented Individuals. 2019 , 67, 411-422 | | 6 |
| 280 | Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease. 2019 , 10, 922-930 | | 4 |
| 279 | Treating Alzheimer's disease by targeting iron. 2019 , 176, 3622-3635 | | 37 |
| 278 | Amyloid- β immunotherapy for alzheimer disease: Is it now a long shot?. 2019 , 85, 303-315 | | 87 |
| 277 | Procyanidins and Alzheimer's Disease. 2019 , 56, 5556-5567 | | 26 |
| 276 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. 2019 , 9, 31-61 | | 33 |
| 275 | The protective role of endogenous n-3 polyunsaturated fatty acids in Tau Alzheimer's disease mouse model. 2019 , 129, 325-336 | | 5 |
| 274 | Rationale for the development of an Alzheimer's disease vaccine. 2020 , 16, 645-653 | | 5 |

| | | |
|-----|--|-----|
| 273 | Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer's disease. 2020 , 142, 265-276 | 14 |
| 272 | BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. 2020 , 40, 339-384 | 90 |
| 271 | The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. 2020 , 16, 1553-1560 | 72 |
| 270 | Concordance of Lumipulse cerebrospinal fluid t-tau/A β 2 ratio with amyloid PET status. 2020 , 16, 144-152 | 22 |
| 269 | A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers. 2020 , 42, 108-120.e1 | 9 |
| 268 | Dengzhan Shengmai capsules and their active component scutellarin prevent cognitive decline in APP/PS1 mice by accelerating A β aggregation and reducing oligomers formation. 2020 , 121, 109682 | 3 |
| 267 | The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension. 2020 , 3, 21-28 | 6 |
| 266 | Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. 2020 , 16, 30-42 | 171 |
| 265 | Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid- β attenuation. 2020 , 143, 359-373 | 20 |
| 264 | Amyloid- β -Independent regulators of tau pathology in Alzheimer disease. 2020 , 21, 21-35 | 176 |
| 263 | Status and future directions of clinical trials in Alzheimer's disease. 2020 , 154, 3-50 | 13 |
| 262 | Alzheimer's disease: Recent treatment strategies. 2020 , 887, 173554 | 95 |
| 261 | Kinetic fingerprints differentiate the mechanisms of action of anti-A β antibodies. 2020 , 27, 1125-1133 | 35 |
| 260 | Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia. 2020 , 21, | 5 |
| 259 | Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. 2020 , 29, 919-933 | 12 |
| 258 | Alzheimer's disease drug development pipeline: 2020. 2020 , 6, e12050 | 161 |
| 257 | Anti-A β antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology. 2020 , 8, 198 | 2 |
| 256 | Apolipoprotein J in Alzheimer's Disease: Shedding Light on Its Role with Cell Signaling Pathway Perspective and Possible Therapeutic Approaches. 2020 , 11, 4060-4072 | 0 |

| | | |
|-----|--|------|
| 255 | Modeling neurodegenerative diseases with cerebral organoids and other three-dimensional culture systems: focus on Alzheimer's disease. 2020 , 1 | 9 |
| 254 | Index. 2020 , 160-162 | |
| 253 | Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease. 2020 , 59, 100857 | 26 |
| 252 | Anti-amyloid- β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. 2020 , 25, 319-335 | 30 |
| 251 | The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease. 2020 , 21, | 9 |
| 250 | A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. 2020 , 16, 1412-1425 | 32 |
| 249 | Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 95 | 9 85 |
| 248 | Computational Investigation of Gantenerumab and Crenezumab Recognition of A β Fibrils in Alzheimer's Disease Brain Tissue. 2020 , 11, 3233-3244 | 4 |
| 247 | Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. 2020 , 11, 1986 | 48 |
| 246 | Amyloidosis increase is not attenuated by long-term calorie restriction or related to neuron density in the prefrontal cortex of extremely aged rhesus macaques. 2020 , 42, 1733-1749 | 7 |
| 245 | Revisiting the Amyloid Cascade Hypothesis: From Anti-A β Therapeutics to Auspicious New Ways for Alzheimer's Disease. 2020 , 21, | 42 |
| 244 | Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. 2020 , 49, 334-348 | 12 |
| 243 | Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer's Disease. 2020 , 21, | 10 |
| 242 | New therapeutics beyond amyloid- β and tau for the treatment of Alzheimer's disease. 2021 , 42, 1382-1389 | 18 |
| 241 | Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. 2020 , 21, | 4 |
| 240 | Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. 2020 , 8, 74 | 7 |
| 239 | Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairment-A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters. 2020 , 14, 179 | 12 |
| 238 | N-terminal heterogeneity of parenchymal and vascular amyloid- β deposits in Alzheimer's disease. 2020 , 46, 673-685 | 12 |

- 237 Alzheimer's: Are we winning the fight? Not so sure. **2020**, 176, 299-300 2
- 236 AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. **2020**, 11, 459 6
- 235 [Pharmacological prevention of cognitive decline and dementia]. **2020**, 63, 506-511 2
- 234 Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls. **2020**, 3, 472-488 6
- 233 Current and Future Treatments in Alzheimer Disease: An Update. **2020**, 12, 1179573520907397 137
- 232 The Hypothesis That Refuses to Die. **2020**, 95-104
- 231 Preface 1 The Question. **2020**, ix-x
- 230 The Shaky Six and the Second Reality 2020, 1-10
- 229 Pieces of a Puzzle?. **2020**, 11-24
- 228 Disease Redefinition A Tough Pill to Swallow. **2020**, 25-32
- 227 Disease Subtypes: The Promise and the Fallacy. **2020**, 33-40
- 226 Protein Paradox. **2020**, 41-56
- 225 The Fault in Our Models. **2020**, 57-70
- 224 Biomarkers: The Promise and the Fallacy. **2020**, 71-80
- 223 Lessons from Oncology. **2020**, 81-86
- 222 Symptomatic vs. Disease-Modifying Therapies. **2020**, 87-94 0
- 221 Our Living Dissonance. **2020**, 105-110
- 220 The Scientific and Lay Narratives. **2020**, 111-124

219 Challenges Viewed from Afar. **2020**, 125-132

218 The Moonshot: Population-Based Studies of Aging. **2020**, 133-138

217 Predictions for the 2020s and Beyond. **2020**, 139-147

216 Note Added at Press Time [Reviving LOF. **2020**, 150-150

215 References. **2020**, 151-159

214 Epilogue. **2020**, 148-149

213 P33 Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab. **2020**, 131, e195

212 Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. **2020**, 97, 103649 39

211 Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. **2020**, 177, 2860-2871 3

210 Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment. **2020**, 35, 1533317519899800 7

209 Traitement de la maladie d'Alzheimer : une lueur au bout du tunnel ?. **2020**, 11, 46-48

208 Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. **2020**, 139, 104823 9

207 Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice: Position paper of the Dementia and Cognitive Disorders Panel of the European Academy of Neurology. **2020**, 27, 928-943 34

206 Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets. **2020**, 17, 935-954 15

205 Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. **2020**, 16, 797-803 1

204 What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. **2020**, 155, 120-136 16

203 Passive anti-amyloid immunotherapy for Alzheimer's disease. **2020**, 33, 284-291 23

202 Hippocampal Deficits in Amyloid- β -Related Rodent Models of Alzheimer's Disease. **2020**, 14, 266 16

| | | |
|-----|--|-----|
| 201 | Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy. 2020 , 2020, 5380346 | 33 |
| 200 | Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty. 2020 , 11, 261 | 22 |
| 199 | The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. 2021 , 27, 6-12 | 24 |
| 198 | Tau PET imaging with F-PI-2620 in aging and neurodegenerative diseases. 2021 , 48, 2233-2244 | 20 |
| 197 | Early detection and personalized medicine: Future strategies against Alzheimer's disease. 2021 , 177, 157-173 | 1 |
| 196 | β Amyloid: The known unknowns. 2021 , 65, 101212 | 13 |
| 195 | Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. 2021 , 64, 926-937 | 2 |
| 194 | Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. 2021 , 17, 696-701 | 107 |
| 193 | Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials. 2021 , 28, e1 | 6 |
| 192 | A comparative study on the application of machine learning algorithms for neurodegenerative disease prediction. 2021 , 283-302 | |
| 191 | Lipidomic Analysis of Postmortem Prefrontal Cortex Phospholipids Reveals Changes in 'Choline Plasmalogen Containing Docosahexaenoic Acid' and Stearic Acid Between Cases With and Without Alzheimer's Disease. 2021 , 23, 161-175 | 5 |
| 190 | Monoclonal Antibodies as Neurological Therapeutics. 2021 , 14, | 12 |
| 189 | Association of naturally occurring antibodies to β Amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. 2021 , 7, | 8 |
| 188 | Power and sample size for random coefficient regression models in randomized experiments with monotone missing data. 2021 , 63, 806-824 | 1 |
| 187 | Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. 2021 , 121, 2545-2647 | 128 |
| 186 | Role of Retinal Amyloid-β In Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. 2021 , 22, | 8 |
| 185 | APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. 2021 , 13, | 23 |
| 184 | Geroprotective effects of Alzheimer's disease drug candidates. 2021 , 13, 3269-3289 | 4 |

| | | |
|-----|--|------|
| 183 | Linolenic acid induces clearance of Tau seeds via Actin-remodeling in Microglia.. 2021 , 2, 4 | 5 |
| 182 | Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans. 2021 , 26, 52-61 | 6 |
| 181 | Quantification of N-terminal amyloid- β isoforms reveals isomers are the most abundant form of the amyloid- β peptide in sporadic Alzheimer's disease. 2021 , 3, fcab028 | 6 |
| 180 | The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. 2021 , 22, | 2 |
| 179 | The role of biofactors in the prevention and treatment of age-related diseases. 2021 , 47, 522-550 | 4 |
| 178 | Recent advances in pre-clinical diagnosis of Alzheimer's disease. 2021 , 1 | |
| 177 | Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer's disease. | |
| 176 | Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics. 2021 , 11, | 2 |
| 175 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 80 | 9 92 |
| 174 | Increasing phagocytosis of microglia through targeting CD33 with liposomes displaying glycan ligands. | |
| 173 | On Gaps of Clinical Diagnosis of Dementia Subtypes: A Study of Alzheimer's Disease and Lewy Body Disease. | |
| 172 | Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. 2021 , 13, | 14 |
| 171 | Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation. 2021 , 21, 969-990 | 1 |
| 170 | Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. 2021 , 82, 71-105 | 7 |
| 169 | Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. 2021 , 26, 1330-1336 | 1 |
| 168 | Ganoderic Acid A Promotes Amyloid- β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer's Disease (Mouse Model) through Autophagy Induced by Activating Axl. 2021 , 22, | 4 |
| 167 | Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease. 2021 , 17, 1051-1055 | 5 |
| 166 | Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. 2021 , 22, | 6 |

| | | |
|-----|--|----|
| 165 | Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease. 2021 , 48, 5629-5645 | 14 |
| 164 | Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. 2021 , 22, | 8 |
| 163 | Immunotherapies for Neurodegenerative Diseases. 2021 , 12, 654739 | 3 |
| 162 | Decreased MEF2A Expression Regulated by Its Enhancer Methylation Inhibits Autophagy and May Play an Important Role in the Progression of Alzheimer's Disease. 2021 , 15, 682247 | 1 |
| 161 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. 2021 , 27, 1187-1196 | 51 |
| 160 | Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends. 2021 , 139, 111634 | 0 |
| 159 | The Progress of Label-Free Optical Imaging in Alzheimer's Disease Screening and Diagnosis. 2021 , 13, 699024 | 1 |
| 158 | Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective. 2021 , 181, 1276-1278 | 44 |
| 157 | Passive immunotherapy with a novel antibody against 3pE-modified A β demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. 2021 , 154, 105365 | 3 |
| 156 | Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. 2021 , 13, e14398 | 8 |
| 155 | The complexity of Alzheimer's disease: an evolving puzzle. 2021 , 101, 1047-1081 | 7 |
| 154 | Therapy for Alzheimer's disease: Missing targets and functional markers?. 2021 , 68, 101318 | 3 |
| 153 | Effects of monoclonal antibodies against amyloid- β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. 2021 , 68, 101339 | 24 |
| 152 | Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. 2021 , 22, | 3 |
| 151 | On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes. 2021 , 18, 714-723 | 0 |
| 150 | Novel bioengineered MBenes for the treatment of Alzheimer's disease: An in-Sillico study. 2021 , 1-9 | 2 |
| 149 | GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease. 2021 , 116, 146-159 | 14 |
| 148 | Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. 2021 , 26, | 2 |

| | | |
|-----|--|----|
| 147 | Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. 2021 , 12, 694329 | 2 |
| 146 | Treatments for Alzheimer's disease emerge. 2021 , 373, 624-626 | 21 |
| 145 | Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease. 2021 , 90, 331-333 | 3 |
| 144 | Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. 2021 , 39, 134-140 | 0 |
| 143 | Are Parkinson's Disease Patients the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?. 2021 , 11, | 0 |
| 142 | Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. 2021 , 8919887211044746 | 7 |
| 141 | Novel Plasma miRNAs as Biomarkers and Therapeutic Targets of Alzheimer's Disease at the Prodromal Stage. 2021 , 83, 779-790 | 3 |
| 140 | Diagnosis and Treatment of Alzheimer's Disease:: An Update. 2021 , 7, 74-85 | 1 |
| 139 | Molecular Insights into the Inhibitory Effect of GV971 Components Derived from Marine Acidic Oligosaccharides against the Conformational Transition of A β 2 Monomers. 2021 , 12, 3772-3784 | 1 |
| 138 | The Rhesus Macaque as a Translational Model for Neurodegeneration and Alzheimer's Disease. 2021 , 13, 734173 | 1 |
| 137 | Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis. 2021 , 4, e2124124 | 6 |
| 136 | Citrullination of Amyloid- β Peptides in Alzheimer's Disease. 2021 , 12, 3719-3732 | 2 |
| 135 | Amyloid- β and Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. 2021 , 15, 733857 | 8 |
| 134 | Increasing phagocytosis of microglia by targeting CD33 with liposomes displaying glycan ligands. 2021 , 338, 680-693 | 1 |
| 133 | SLCO1B1 & ApoE Gene Polymorphism Analysis of the Li People in Hainan Island and Its Clinical Significance. 2021 , 14, 130-141 | 1 |
| 132 | The Ups and Downs of Amyloid in Alzheimer's.. 2022 , 9, 92-95 | 1 |
| 131 | Alzheimer's Disease Pharmacology. 2021 , | 1 |
| 130 | Advances in Drug Therapy for Alzheimer's Disease. 2020 , 40, 999-1008 | 3 |

| | | |
|-----|--|----|
| 129 | Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them. 2020, | 2 |
| 128 | Iron Responsive Element (IRE)-mediated responses to iron dyshomeostasis in Alzheimer's disease. | 6 |
| 127 | Kinetic fingerprints differentiate anti-A β therapies. | 5 |
| 126 | The Future of Anti-Amyloid Trials. 2020, 7, 146-151 | 20 |
| 125 | Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. 2021, 8, 3-6 | 9 |
| 124 | The neuroprotective effects of SIRT1 in mice carrying the APP/PS1 double-transgenic mutation and in SH-SY5Y cells over-expressing human APP670/671 may involve elevated levels of α 7 nicotinic acetylcholine receptors. 2020, 12, 1792-1807 | 8 |
| 123 | A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. 2020, 26, 1286-1299 | 6 |
| 122 | Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies. 2020, 21, 148-166 | 7 |
| 121 | Therapeutic Strategies Targeting Amyloid- β in Alzheimer's Disease. 2019, 16, 418-452 | 32 |
| 120 | Glycemic Control is Related to Cognitive Dysfunction in Elderly People with Type 2 Diabetes Mellitus in a Rural Chinese Population. 2019, 16, 950-962 | 5 |
| 119 | Genetic Variants and Oxidative Stress in Alzheimer's Disease. 2020, 17, 208-223 | 12 |
| 118 | Mechanistic Modeling of Soluble A β Dynamics and Target Engagement in the Brain by Anti-A β mAbs in Alzheimer's Disease. 2020, 17, 393-406 | 2 |
| 117 | Phosphorylation and Glycosylation of Amyloid- β Protein Precursor: The Relationship to Trafficking and Cleavage in Alzheimer's Disease. 2021, 84, 937-957 | 1 |
| 116 | Past, present and future of therapeutic strategies against amyloid- β peptides in Alzheimer's disease: a systematic review. 2021, 72, 101496 | 13 |
| 115 | An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure. 2021, 22, | 2 |
| 114 | The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis. 2021, 72, 101491 | 3 |
| 113 | Alzheimer's disease clinical trial update 2019-2021. 2021, 1 | 6 |
| 112 | Therapeutic antibodies - natural and pathological barriers and strategies to overcome them. 2021, 108022 | 1 |

- 111 Novel API Coated Catheter Removes Amyloid- β from Plasma of Patients with Alzheimer's Disease. **2021**, 7,
- 110 Que penser de l'approche m'edicamenteuse pr'eventive de la maladie d'Alzheimer ?. **2018**, 202, 679-690
- 109 Alzheimer's Disease - Clinical Trials. 8,
- 108 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 107 Thiamine pyrophosphokinase deficiency induces Alzheimer's pathology.
- 106 Preface 2 [Enter Patient. **2020**, xi-xii
- 105 Alzheimer's drugs: Does reducing amyloid work?. **2021**, 374, 544-545 1
- 104 Immunotherapy Targeting Amyloid- β Peptides in Alzheimer's Disease. 23-49 1
- 103 Pharmacogenomic approaches to the treatment of sporadic Alzheimer's disease. **2020**, 81-94
- 102 Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. **2021**, 2
- 101 [Disease-modifying treatment approaches for Alzheimer's disease]. **2021**, 92, 1239-1248 1
- 100 [The future of dementia prevention and treatment strategies]. **2020**, 57, 374-396
- 99 Intense Focus Yet Many Setbacks for Alzheimer's Disease Drug Development. **2018**, 43, 234-248
- 98 The landscape of metabolic brain alterations in Alzheimer's disease. 1
- 97 Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. **2021**, 3
- 96 Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. **2021**, 36
- 95 Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab.. **2022**, 53, 298-302 0
- 94 Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.. **2022**, 9, 211-220 1

| | | |
|----|---|----|
| 93 | Amyloid-Related Imaging Abnormalities and β Amyloid-Targeting Antibodies: A Systematic Review.. 2022, | 4 |
| 92 | A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro.. 2022, 17, e0261696 | 0 |
| 91 | Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.. 2022, | 0 |
| 90 | The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.. 2021, | 2 |
| 89 | Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.. 2022, 919, 174800 | 1 |
| 88 | Introduction. 2022, 1-14 | |
| 87 | New Perspectives for Treatment in Alzheimer's Disease. 2022, 199-225 | |
| 86 | Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. 2022, 23, | 3 |
| 85 | The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. 2022, | 24 |
| 84 | Toward Bridging Unmet Medical Need in Early Alzheimer's Disease: An Evaluation of Beta-Amyloid (A β) Plaque Burden as a Potential Drug Development Tool.. 2022, | 0 |
| 83 | Challenges and approaches of drugs such as Memantine, Donepezil, Rivastigmine and Aducanumab in the treatment, control and management of Alzheimer's disease.. 2022, | 1 |
| 82 | Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.. 2022, 56, 501-516 | 1 |
| 81 | Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.. 2022, 12, | 0 |
| 80 | A simulation study on the estimation of the effect in the hypothetical scenario of no use of symptomatic treatment in trials for disease-modifying agents for Alzheimer's disease. 1-21 | 0 |
| 79 | Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease.. 2022, 11, | 4 |
| 78 | Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.. 2022, | 3 |
| 77 | Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.. 2022, 13, 862369 | 1 |
| 76 | Brain Imaging for Alzheimer's Disease Clinical Trials. 2022, 375-394 | |

| | | |
|----|--|---|
| 75 | Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures.. 2022 , | 5 |
| 74 | Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease.. 2022 , 36, 365 | 2 |
| 73 | [Causal treatment of Alzheimer's disease: amyloid antibodies].. 2022 , 1 | |
| 72 | Development of Fluid Biomarkers for Alzheimer's Disease. 2022 , 361-374 | |
| 71 | Quantification of amyloid PET for future clinical use: a state-of-the-art review.. 2022 , 1 | 1 |
| 70 | Vascular risk burden is a key player in the early progression of Alzheimer's disease. | |
| 69 | Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes.. 2021 , | |
| 68 | Complement System in Alzheimer's Disease.. 2021 , 22, | 3 |
| 67 | Blood-based biomarkers for Alzheimer's disease. 2021 , e14408 | 7 |
| 66 | Impact of Anti-amyloid- β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.. 2022 , 14, 870517 | 8 |
| 65 | The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report. | 0 |
| 64 | Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials. 1 | 1 |
| 63 | Presenilin/ β Secretase in the Pathogenesis of Alzheimer's Disease. 2022 , 325-334 | |
| 62 | Alzheimer's disease drug development pipeline: 2022.. 2022 , 8, e12295 | 7 |
| 61 | ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.. 2022 , 16, 848215 | 1 |
| 60 | Amyloid-beta targeted therapeutic approaches for Alzheimer's disease: long road ahead.. 2022 , | 0 |
| 59 | Shared pathophysiology: Understanding stroke and Alzheimer's disease. 2022 , 218, 107306 | 2 |
| 58 | Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer's Disease. 14, | 0 |

| | | |
|----|--|----|
| 57 | Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. 2022 , 14, 1117 | 13 |
| 56 | Recent Updates on PET Imaging in Neurodegenerative Diseases. 2022 , 83, 453 | |
| 55 | Physiological Roles of Monomeric Amyloid- β and Implications for Alzheimer's Disease Therapeutics. 2022 , 31, 65-88 | 3 |
| 54 | Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. | 5 |
| 53 | Rational drug design strategies for the development of promising multi-target directed indole hybrids as Anti-Alzheimer agents. 2022 , 127, 105941 | 2 |
| 52 | Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia. 2022 , 8, | |
| 51 | Insights for Alzheimer's disease pharmacotherapy and current clinical trials. 2022 , 105401 | 0 |
| 50 | Anti-amyloid therapy of Alzheimer's disease: origins, current state and prospects of development. 2022 , LIV, 56-68 | |
| 49 | Pharmacotherapy for Alzheimer's disease: what's new on the horizon?. 1-19 | |
| 48 | Alzheimer diseases. 2023 , 313-336 | 0 |
| 47 | Are we ready to use anti-amyloid therapy in Alzheimer's disease?. 2022 , 80, 15-23 | 0 |
| 46 | Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. | 0 |
| 45 | The Pivotal Role of NF- κ B in the Pathogenesis and Therapeutics of Alzheimer's Disease. 2022 , 23, 8972 | 2 |
| 44 | The landscape of m6A regulators in multiple brain regions of Alzheimer's Disease. | 0 |
| 43 | Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease. 2022 , 23, 9777 | 2 |
| 42 | High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. 2022 , | 1 |
| 41 | Immunotherapies for Alzheimer's Disease: A Review. 2022 , 10, 1527 | 0 |
| 40 | Predicting conversion of brain β -amyloid positivity in amyloid-negative individuals. 2022 , 14, | 0 |

| | | |
|----|--|---|
| 39 | Path integration deficits with phosphorylated tau accumulation in the entorhinal cortex in mice and humans. | 0 |
| 38 | Amyloid-related imaging abnormalities in the DIAN-TU -001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. | 0 |
| 37 | Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. | 1 |
| 36 | Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. | 2 |
| 35 | Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease. | 0 |
| 34 | Quantitative Systems Pharmacology Model of the Amyloid Pathway in Alzheimer's Disease: Insights into the Therapeutic Mechanisms of Clinical Candidates. | 0 |
| 33 | Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer's Drugs. 2022 , 14, 2296 | 3 |
| 32 | Lecanemab, Aducanumab, and Gantenerumab Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. | 4 |
| 31 | An update on the novel and approved drugs for Alzheimer disease. 2022 , | 2 |
| 30 | Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias. 2022 , | 0 |
| 29 | Amyloid-Related Imaging Abnormalities: An Update. | 0 |
| 28 | Biologics for the management of dementia. 2023 , 193-234 | 0 |
| 27 | Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. 2022 , 14, | 0 |
| 26 | Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. 2023 , 18, 275-279 | 0 |
| 25 | Science disconnected: the translational gap between basic science, clinical trials, and patient care in Alzheimer's disease. 2022 , 3, e797-e803 | 0 |
| 24 | Comparing ARIA-E severity scales and effects of treatment management thresholds. 2022 , 14, | 0 |
| 23 | Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease. 2022 , 22, 863-873 | 0 |
| 22 | Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. 2022 , 14, | 1 |

| | | |
|----|--|---|
| 21 | Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimer's Disease Clinical Trials. 2022 , 1-5 | 0 |
| 20 | Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). | 0 |
| 19 | Emerging Therapeutics Agents and Recent Advances in Drug Repurposing for Alzheimer's Disease. 2022 , 101815 | 0 |
| 18 | Brain pharmacokinetics of mono- and bispecific amyloid- β antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis. 2022 , 19, | 0 |
| 17 | Role of monomeric amyloid- β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. 2023 , 187, 106631 | 0 |
| 16 | Links between COVID-19 and Parkinson's disease/Alzheimer's disease: reciprocal impacts, medical care strategies and underlying mechanisms. 2023 , 12, | 1 |
| 15 | Advances in Alzheimer's disease's pharmacological treatment. 14, | 1 |
| 14 | Anti-amyloid antibody therapies in Alzheimer's disease. | 1 |
| 13 | Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. 2023 , 15, | 0 |
| 12 | FDA approval of lecanemab: the real start of widespread amyloid PET use? The EANM Neuroimaging Committee perspective. | 0 |
| 11 | TG2 promotes amyloid beta aggregates: Impact on ER-mitochondria crosstalk, calcium homeostasis and synaptic function in Alzheimer's disease. 2023 , 162, 114596 | 0 |
| 10 | Disease-modifying vs symptomatic treatments: Splitting over lumping. 2023 , 187-209 | 0 |
| 9 | Lessons from anti-amyloid- β immunotherapies in Alzheimer's disease. 2023 , 267-292 | 0 |
| 8 | Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery. 2023 , 15, 746 | 0 |
| 7 | Aducanumab: Hope or Disappointment for Alzheimer's Disease. 2023 , 24, 4367 | 0 |
| 6 | Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease. 14, | 0 |
| 5 | On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer's disease and Lewy body disease. 15, | 0 |
| 4 | Amyloid inhibition by molecular chaperones in vitro can be translated to Alzheimer's pathology in vivo. | 0 |

- 3 Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies. **2023**, 25, 121-133 ○
- 2 New Insights into Alzheimer's Disease: Novel Pathogenesis, Drug Target and Delivery. **2023**, 15, 1133 ○
- 1 Magnetic Iron Oxide Nanoparticles for Brain Imaging and Drug Delivery. **2023**, 114822 ○